High Prevalence of HIV-1 Drug Resistance and Dynamics of Transmission Among High-Risk Populations in Port-au-Prince, Haiti.
PMID: 33136738
2020
Journal of acquired immune deficiency syndromes (1999)
Abstract: Five clusters (62.5%) had shared DRMs, and K103N and M184V were the main shared mutations.
Result: Five clusters had shared resistance mutations, and K103N (14/24) and M184V (12/24) were the main DRM shared.
Result: Of the DRM, K103N (46/119; 38.6%), which causes high-level resistance to efavirenz and nevirapine, and M184V (35/119; 29.4%), associated with TDF and Emtricitabine (FTC) resistance, were the most frequently observed.
Result: Resistance mutations were detected in 1 of the 5 individuals classified as recently infected (NNRTI: K103N; K101E).
In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix.
Result: Baseline genotype (pre-PI) indicated that the individual had developed extensive resistance to first-line ART, with the nucleoside reverse transcriptase inhibitor (NRTI) mutations K65R and M184I conferring high-level tenofovir and lamivudine resistance, respectively, as well as K103N and Y181C conferring resistance to nonnucleoside reverse transcriptase inhibitors (NNRTI).
Result: Of note, we observed loss of mutations affecting susceptibility to lamivudine (M184I), tenofovir (K65R), and efavirenz (K103N) between baseline and VF1.
Table:
The genotype distribution, infection stage and drug resistance mutation profile of human immunodeficiency virus-1 among the infected blood donors from five Chinese blood centers, 2014-2017.
Abstract: 48 DRMs were identified from 43 samples, indicating a drug resistance prevalence of 12.1% (43/356), which include seven protease inhibitors (PIs) accessory DRMs (Q58E, L23I and I84M), two PIs major DRMs (M46I, M46L), seven nucleoside RT inhibitors DRMs (D67N, K70Q, K219R and M184L), and 32 non-nucleoside RT inhibitors DRMs (K103N, V179E, K238N, V179D, PMID: 33364799
2020
Infection and drug resistance
Result: The most common RAMs to NRTIs were M184V and K65R (1.3%), while those for NNRTIs were V179D (4.5%), V106I (2.7%), and K103N (1.3%), and those for PIs were L10I (13.4%), A71T (5.8%), and L10V (4.0%).
Figure: The figure shows that the most common drug resistance-associated mutations were M184V (1.3%) and K65R (1.3%) for NRTIs, V179D (4.5%), V106I (2.7%) and K103N (1.3%) for PMID: 33654530
2020
The Pan African medical journal
Result: Predominant NNRTIs mutations were K103N, Y181C, G190A, H221Y, and K101E; NRTIs were M184V, Y115F, K65R, K70R, D67N and PIs were I54V, F53L and V82A (Table 2).
Discussion: Major mutations conferring resistance to NNRTIs with K103N, Y181C, H22Y, G190A
[Prevalence of transmitted drug resistance in HIV-infected treatment-naive patients in Chile].
Abstract: The mutations in reverse transcriptase were M41L, L210W, D67N, K70E, M184V, K103N (6.36%, 95% CI 3.5-10.4), G190A, E138A, K101E, and I84V in protease.
Use of a mutation-specific genotyping method to assess for HIV-1 drug resistance in antiretroviral-naive HIV-1 Subtype C-infected patients in Botswana.
Result: PANDAA identified the presence of K103N in three samples.
Result: PANDAA was completed on patient-derived amplicons of 103 ARV naive individuals for the K103N, V106M and M184V DRMs using PANDAA.
Result: The three samples with K103N were the same samples that Sanger sequencing detected.
Discussion: By using PANDAA, we targeted the most likely mutations to develop to these medications in HIV-1 subtype C, the M184V, K103N and V106M mutations in reverse transcriptase, a targeted and cost-effective approach to genotyping is possible .
Discussion: Common drug resistance mutations associated with resistance to efavirenz include
Discovery, synthesis, and optimization of an N-alkoxy indolylacetamide against HIV-1 carrying NNRTI-resistant mutations from the Isatis indigotica root.
PMID: 32004936
2020
European journal of medicinal chemistry
Abstract: Especially, 10i (EC50 = 0.43 muM) was more active to the L100I/K103N double-mutant strain as compared to both NVP (EC50 = 0.76 muM) and EFV (EC50 = 1.08 muM).
Method: The complex structure was obtained from the Protein Data Bank (WT RT: 1TL1, Y181C RT: 1JLB, K103N-Y181C double-mutated RT: 5VQY, L100I-K103N double-mutated RT: 2ZE2).
Result: Among these, K103N, Y181C or Y188L, carried by RT, are the most prevalent mutants.
Result: As t
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
PMID: 31976534
2020
The Journal of antimicrobial chemotherapy
Abstract: In comparison, the prevalence of the common NNRTI mutations V90I, K101E/P, K103N/S, E138A/G/K/Q/R/S, Y181C/I/V and G190A/E/S/Q were higher (8.9%, 7.9%, 28.6%, 12.6%, 14.2% and 8.9%, respectively).
Abstract: RESULTS: The frequencies of doravirine-associated resistance mutations (total dataset versus NNRTI-failing patients) were: V106A/M, 0.8% versus 2.6%; V108I, 3.3% versus 9.2%; Y188L, 1.2% versus 2.6%; G190S, 0.3% versus 2.1%; F227C/L/V
Pre-treatment HIV-drug resistance associated with virologic outcome of first-line NNRTI-antiretroviral therapy: A cohort study in Kenya.
Result: 35,428 copies/mL, p = 0 0032), including those with single Y181C, M184V or G190A mutations, and those with multiple NNRTI/NRTI mutations, but not among those with single K103N mutations (Table 3).
Result: Among participants taking NVP-ART, those with a single K103N or multiple NNRTI/NRTI mutations had higher rates of virologic failure compared to those with no PDR mutations (Table 2).
Result: Among the 59 participants with PDR, NNRTI mutations (K103N, Y181C, G190A) were detected in all but one (98 3%) and <
HIV mutation literature information.
PMID: 
2020
Journal of acquired immune deficiency syndromes (1999)
Browser Board
Co-occurred Entities
Filtrator
ViMRT